Ponsegromab - Pfizer
Alternative Names: PF 06946860Latest Information Update: 18 Sep 2025
At a glance
- Originator Pfizer
- Class Appetite stimulants; Heart failure therapies; Monoclonal antibodies
- Mechanism of Action Growth differentiation factor 15 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cachexia
- Discontinued Heart failure
Most Recent Events
- 30 May 2025 Efficacy data from a phase II trial in Cachexia presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 25 May 2025 Pfizer plans a phase IIb/III trial in Cachexia (SC)(NCT06989437)
- 23 Apr 2025 Pfizer completes a Phase II trial in Cachexia in Australia, Bulgaria, Canada, China, France, Hungary, Japan, Poland, Slovakia, Spain, Taiwan and USA (SC) (NCT05546476)